Thirteen projects awarded under the 2024 subsidy round of the Efficiency Research program by ZonMw

The Dutch Organization for Health Research and Development (ZonMw) works to improve disease prevention, healthcare practices, and the health status of Dutch citizens by stimulating and funding research, development, and implementation of innovative technologies.

The ZonMw Efficiency Research program is intended to develop socially relevant and high-quality knowledge about the effectiveness and costs of innovative and existing non-pharmaceutical diagnostic and therapeutic interventions within the basic insurance package or long-term care. 

The following types of projects are eligible for the Efficiency Research program:

• The project provides knowledge about the effectiveness and costs of non-pharmacotherapeutic interventions;

• The project is a comparison of intervention with standard care;

• The project concerns comparative research into interventions with proven safety and plausible efficacy.

At the beginning of July 2023, 13 projects were awarded funding under the 2024 Round of the Efficiency Research program. The grant is intended to conduct research into which treatment method gives the best result and at what cost. 

Below are some examples of the awarded projects:

• Bowel surgery in Crohn's disease: comparison of different suturing techniques;

• Costs and effectiveness of regular therapy in anxiety disorders;

• Surgery or waiting in children with a congenital skull disorder (wedge-shaped skull);

• New diagnosis strategy for children with acute abdominal pain at primary care;

• Effectiveness of direct use of intensive therapy in post-traumatic stress disorder.

The projects will start by the end of 2023.

The full details in Dutch can be found here. 

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.